Accelerating Innovation in Life Sciences CRM
Preparing for the Future of Engagement
The life sciences sector is undergoing a significant transformation as Veeva Systems and Salesforce, two leaders in customer relationship management (CRM) solutions, prepare to end their nearly two-decade-long partnership in September 2025. This decision marks the start of a five-year migration period, during which existing Veeva CRM customers can continue using the platform on Salesforce while transitioning to alternative solutions. For organizations in this highly regulated industry, the split presents a pivotal opportunity to reassess commercial Go-to-Market CRM strategies and align with future business needs.
Veeva and Salesforce have long collaborated to shape CRM innovation in life sciences, seamlessly blending Veeva's deep industry expertise with Salesforce's robust platform infrastructure. Now, as both companies refocus their priorities, this separation positions them to independently pursue tailored growth and innovation strategies that align with their strengths while expanding their capabilities.
By 2030, the migration will conclude, signaling the end of Veeva CRM on Salesforce. Organizations are encouraged to proactively transition to either Veeva Vault CRM or Salesforce Life Sciences Cloud to ensure they are prepared for this new chapter in the evolving CRM landscape.
Rather than marking the end of an era, this move signals a new chapter for both companies. By pursuing tailored approaches to innovation, Veeva and Salesforce remain committed to empowering life sciences organizations with the tools to succeed in an evolving industry.
The Challenges & Opportunities for Life Sciences Companies
The separation of these CRM titans brings both potential risks and rewards to life sciences companies, who now must decide whether to evolve with Veeva Vault CRM or explore Salesforce’s emerging Life Sciences Cloud option. Regardless of their decision, careful strategic planning will be required for companies that want to mitigate challenges and seize opportunities.
Challenges
- Strategic Reassessment: Life sciences organizations will need to reevaluate their commercial go-to-market strategies, operational goals and technological and CRM ecosystems by the September 2030 migration deadline.
- Migration Complexity: Transitioning data and integrations from Salesforce-based Veeva CRM to Vault CRM or to Salesforce Life Sciences Cloud can be resource-intensive and lengthy.
- Managing Program Adoption: Companies will need cross-functional and operational change management during migration, with efforts to drive new platform adoption and ways of working.
Opportunities
- Competitive CRM Innovations: The split is fostering competition between Veeva and Salesforce, which promises better offerings and continuous innovation tailored to the life sciences sector.
- Expanded Functionality: Both Veeva and Salesforce now have the freedom to develop their own platforms — potentially integrating capabilities that leverage AI, analytics and ecosystem partnerships to suit specific commercial challenges.
- Navigating New Verticals: With Veeva exploring MedTech and beyond, life sciences companies operating in adjacent fields may see enhanced solutions and services.
Evaluating the Right CRM Path Forward
When life sciences companies evaluate CRM solutions, the decision between Veeva Vault CRM and Salesforce Life Sciences Cloud shouldn’t be framed as simply, “Which one is better?” since a one-size-fits-all approach won’t suffice. This is much more than a technology investment — it’s an operational choice that can shape your company’s trajectory well into 2040 and beyond. Instead, the questions you ask should center around assessing your company’s unique business needs, long-term strategy and customer engagement model.
Questions to Guide Your Decision
To make the decision clearer, companies should begin with self-assessment and future-proof planning. Consider these critical questions:
- What is our long-term commercial vision?
- Where is our revenue coming from today and where do we expect it to come from in the future?
- Who are our key customers and what is their preferred engagement experience?
- What operational milestones or constraints must we navigate? For example, should implementation wait until after a major drug launch, or is it mission-critical to complete before commercialization begins?
By answering these foundational questions, businesses can evaluate their CRM needs accurately. Should the focus be on scaling specialty drug commercialization? Enhancing field rep and patient support workflows? Understanding these engagement models — particularly for key brands representing the majority of revenue — will clarify the best path forward.
Customer engagement needs often vary significantly across organizations. Retail-driven models may prioritize repeat consumer engagement and digital scaling, while specialty drug commercialization may require systems integrated with nurse educators, reimbursement support, and patient services teams. Selecting a platform isn’t simply about contrasting features; it’s about aligning technology with your commercial model and operational priorities.
A Pivotal Moment in CRM Evolution
The Veeva-Salesforce split is much more than a technical transition; it’s a transformative moment in life sciences’ CRM evolution. For many organizations, this disruption serves as a catalyst to reassess their commercial models, data strategies and customer engagement frameworks, and adopt systems that better align with their future business needs. With both Veeva and Salesforce poised to innovate in their respective domains, the ultimate beneficiary will be the life sciences industry itself.
As businesses navigate the complexities of migration and weigh the options available, success will hinge on foresight and thorough analysis by asking and answering right questions. The decision they make today will lay the foundations for tomorrow’s operational efficiency, compliance integrity and competitive advantage. This transition represents an era of informed choice — and therein lies the opportunity.
